HC Wainwright Issues Negative Forecast for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvalent in a report released on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.21) per share for the quarter, down from their previous forecast of ($1.08). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($4.66) EPS and FY2026 earnings at ($3.26) EPS.

Other analysts have also recently issued research reports about the company. Wedbush restated an “outperform” rating and set a $115.00 price objective on shares of Nuvalent in a research note on Monday, January 13th. BMO Capital Markets increased their price target on Nuvalent from $132.00 to $134.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Nuvalent currently has a consensus rating of “Moderate Buy” and an average target price of $113.10.

Nuvalent Stock Up 1.3 %

Shares of NASDAQ NUVL opened at $72.94 on Wednesday. The stock’s 50 day moving average price is $79.50 and its two-hundred day moving average price is $88.29. Nuvalent has a 52-week low of $61.80 and a 52-week high of $113.51. The stock has a market capitalization of $5.18 billion, a P/E ratio of -21.02 and a beta of 1.42.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02).

Insider Buying and Selling at Nuvalent

In other news, CEO James Richard Porter sold 27,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $86.61, for a total transaction of $2,338,470.00. Following the completion of the sale, the chief executive officer now directly owns 188,113 shares of the company’s stock, valued at $16,292,466.93. This trade represents a 12.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Matthew Shair sold 2,000 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $78.43, for a total value of $156,860.00. Following the sale, the director now directly owns 216,522 shares of the company’s stock, valued at approximately $16,981,820.46. This represents a 0.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,800 shares of company stock valued at $8,895,004. 12.52% of the stock is owned by corporate insiders.

Institutional Trading of Nuvalent

A number of hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Nuvalent in the fourth quarter valued at $4,428,000. GF Fund Management CO. LTD. purchased a new stake in shares of Nuvalent in the fourth quarter valued at $108,000. Woodline Partners LP lifted its holdings in shares of Nuvalent by 0.9% in the fourth quarter. Woodline Partners LP now owns 1,204,927 shares of the company’s stock valued at $94,322,000 after purchasing an additional 11,248 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Nuvalent in the fourth quarter valued at $46,968,000. Finally, Soleus Capital Management L.P. lifted its holdings in shares of Nuvalent by 40.3% in the fourth quarter. Soleus Capital Management L.P. now owns 104,357 shares of the company’s stock valued at $8,169,000 after purchasing an additional 30,000 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.